• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于1,3,4-噻二唑和1,3-噻唑烷-4-酮的新型二元杂环分子的合成及其抗增殖效力:基于细胞的抗癌研究

Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: cell-based anticancer studies.

作者信息

Maji Avik, Himaja Ambati, Nikhitha Sripathi, Rana Soumitra, Paul Abhik, Samanta Ajeya, Shee Uday, Mukhopadhyay Chhanda, Ghosh Balaram, Maity Tapan Kumar

机构信息

Synthetic and Natural Products Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University Kolkata-700032 West Bengal India

Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus Hyderabad-500078 India.

出版信息

RSC Med Chem. 2024 Jul 31;15(9):3057-3069. doi: 10.1039/d4md00279b. eCollection 2024 Sep 19.

DOI:10.1039/d4md00279b
PMID:39309361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11411633/
Abstract

Herein, we report the synthesis and anticancer properties of 21 new 1,3,4-thiadiazole-2-yl-imino-thiazolidine-4-one containing binary heterocyclic molecules. Cytotoxicity of the synthesized molecules was evaluated on various cancer cell lines (MCF-7, PC3, 4T1, MDA-MB-231, and MOC2) and normal human embryonic cell lines (HEK-293) MTT assay. The cytotoxicity data of developed compounds was compared with the reference anticancer molecule BG45, a selective inhibitor of the HDAC3 enzyme. All compounds showed a significant cytotoxic effect higher than BG45 on tested cancer cell lines. Moreover, the compounds exhibited better selectivity on cancer cells than on normal cells. Among the molecules, compound 6e is the most potent in cytotoxic activity on MCF-7 cell lines (IC value of 3.85 μM). Additional mechanistic investigation revealed that compound 6e promotes apoptosis (25.3%) and G0/G1 phase cell cycle arrest of MCF-7 cells. Also, compound 6e induces intracellular ROS accumulation and subsequent nuclear fragmentation. Hence, this research finds new hybrid molecules active against cancer cells.

摘要

在此,我们报告了21种新型含1,3,4 - 噻二唑 - 2 - 基 - 亚氨基 - 噻唑烷 - 4 - 酮的二元杂环分子的合成及其抗癌特性。通过MTT法评估了合成分子对多种癌细胞系(MCF - 7、PC3、4T1、MDA - MB - 231和MOC2)以及正常人胚胎细胞系(HEK - 293)的细胞毒性。将所开发化合物的细胞毒性数据与参考抗癌分子BG45(HDAC3酶的选择性抑制剂)进行了比较。所有化合物在测试的癌细胞系上均表现出比BG45更高的显著细胞毒性作用。此外,这些化合物对癌细胞的选择性优于对正常细胞的选择性。在这些分子中,化合物6e对MCF - 7细胞系的细胞毒性活性最强(IC值为3.85 μM)。进一步的机制研究表明,化合物6e可促进MCF - 7细胞凋亡(25.3%)并使其细胞周期停滞于G0/G1期。此外,化合物6e可诱导细胞内活性氧积累及随后的核碎片化。因此,本研究发现了对癌细胞具有活性的新型杂合分子。

相似文献

1
Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: cell-based anticancer studies.基于1,3,4-噻二唑和1,3-噻唑烷-4-酮的新型二元杂环分子的合成及其抗增殖效力:基于细胞的抗癌研究
RSC Med Chem. 2024 Jul 31;15(9):3057-3069. doi: 10.1039/d4md00279b. eCollection 2024 Sep 19.
2
Investigation of cytotoxic activity properties of etoxazole towards human cancer and healthy cell lines and molecular docking studies.乙螨唑对人癌细胞系和健康细胞系的细胞毒性活性特性研究及分子对接研究。
Ann Pharm Fr. 2025 Jul 10. doi: 10.1016/j.pharma.2025.07.001.
3
Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.新型苯磺酰胺类双重 VEGFR2/FGFR1 抑制剂靶向治疗乳腺癌:设计、合成、抗癌活性及计算机模拟研究。
Bioorg Chem. 2024 Nov;152:107728. doi: 10.1016/j.bioorg.2024.107728. Epub 2024 Aug 17.
4
Efficient Synthesis, Anticancer Evaluation of Triazole-Thiadiazole/Benzo[d]Oxazole Scaffolds, and Investigation of Their Reactivity Properties Using Density-Functional Theory Calculations and In Silico Docking.三唑-噻二唑/苯并[d]恶唑支架的高效合成、抗癌评估及其反应性质的密度泛函理论计算和计算机对接研究
Chem Biodivers. 2025 Feb 19:e202402470. doi: 10.1002/cbdv.202402470.
5
Development of novel quinazolinone-based compounds with anti-proliferative activity as dual STAT-3 and c-Src inhibitors: design, synthesis and molecular dynamic studies.新型喹唑啉酮类化合物作为双靶点STAT-3和c-Src抑制剂的抗增殖活性研究:设计、合成及分子动力学研究
Bioorg Chem. 2025 Aug;163:108753. doi: 10.1016/j.bioorg.2025.108753. Epub 2025 Jul 15.
6
Assessment of cytotoxic, anti-proliferative, anti-metastatic, and morphometric effects of Tecoma stans extracts against MDA-MB-231 human breast cancer cell line.评估黄钟花提取物对MDA-MB-231人乳腺癌细胞系的细胞毒性、抗增殖、抗转移和形态测量学作用。
BMC Complement Med Ther. 2025 Jul 12;25(1):261. doi: 10.1186/s12906-025-04992-x.
7
Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase‑carbonic anhydrase inhibitors with potential anti-tubulin activity.基于磺胺的查耳酮杂化物的合成及其凋亡诱导作用,作为具有潜在抗微管蛋白活性的一流双组蛋白脱乙酰酶-碳酸酐酶抑制剂。
Bioorg Chem. 2025 Jun 20;163:108694. doi: 10.1016/j.bioorg.2025.108694.
8
Novel indole Schiff base β-diiminato compound as an anti-cancer agent against triple-negative breast cancer: In vitro anticancer activity evaluation and in vivo acute toxicity study.新型吲哚席夫碱β-二亚胺化合物作为一种针对三阴性乳腺癌的抗癌剂:体外抗癌活性评价和体内急性毒性研究。
Bioorg Chem. 2024 Nov;152:107730. doi: 10.1016/j.bioorg.2024.107730. Epub 2024 Aug 16.
9
Synthesis and anticancer activity evaluation of new linked/fused bioisosteric pyrazole-thiazole-bearing hybrid molecules.新型含吡唑-噻唑连接/稠合生物电子等排体的杂化分子的合成与抗癌活性评价
Bioorg Med Chem. 2025 Oct 1;128:118291. doi: 10.1016/j.bmc.2025.118291. Epub 2025 Jun 22.
10
5-(Thiophen-2-yl)isoxazoles as novel anti-breast cancer agents targeting ERα: synthesis, biological evaluation, studies, and molecular dynamics simulation.5-(噻吩-2-基)异恶唑作为靶向雌激素受体α的新型抗乳腺癌药物:合成、生物学评价、研究及分子动力学模拟
RSC Med Chem. 2025 Jun 25. doi: 10.1039/d5md00339c.

本文引用的文献

1
Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics.TRAIL/Apo-2 配体及其死亡受体在细胞凋亡和 necroptosis 信号转导中的意义:对癌症靶向治疗的启示。
Biochem Pharmacol. 2024 Mar;221:116041. doi: 10.1016/j.bcp.2024.116041. Epub 2024 Feb 3.
2
Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer.载奥沙利铂(Pt(IV))前药白蛋白纳米粒具有双重还原敏感性,可用作三阴性乳腺癌的有效纳米药物。
Int J Biol Macromol. 2024 Jan;256(Pt 1):128281. doi: 10.1016/j.ijbiomac.2023.128281. Epub 2023 Nov 20.
3
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer.选择性 HDAC3 抑制剂对三阴性乳腺癌具有强大的体内抗肿瘤疗效。
J Med Chem. 2023 Sep 14;66(17):12033-12058. doi: 10.1021/acs.jmedchem.3c00614. Epub 2023 Sep 3.
4
Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer.通过表观遗传调节剂、天然和合成药物靶向BCL-2家族蛋白在癌症治疗中的进展。
Eur J Pharmacol. 2023 Apr 5;944:175588. doi: 10.1016/j.ejphar.2023.175588. Epub 2023 Feb 13.
5
Breast Cancer Statistics, 2022.2022 年乳腺癌统计数据。
CA Cancer J Clin. 2022 Nov;72(6):524-541. doi: 10.3322/caac.21754. Epub 2022 Oct 3.
6
Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study.新型具有抗乳腺癌活性的 1,3-噻唑类似物:设计、合成、体外和计算研究。
Molecules. 2022 Jul 31;27(15):4898. doi: 10.3390/molecules27154898.
7
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.新型基于酰肼的小分子选择性抑制组蛋白去乙酰化酶 3 作为癌症治疗的治疗干预。
Eur J Med Chem. 2022 Aug 5;238:114470. doi: 10.1016/j.ejmech.2022.114470. Epub 2022 May 18.
8
New Advances in Targeted Therapy of HER2-Negative Breast Cancer.HER2阴性乳腺癌靶向治疗的新进展
Front Oncol. 2022 Mar 4;12:828438. doi: 10.3389/fonc.2022.828438. eCollection 2022.
9
Oxaliplatin delivery via chitosan/vitamin E conjugate micelles for improved efficacy and MDR-reversal in breast cancer.壳聚糖/维生素 E 缀合物胶束递药用于提高乳腺癌疗效和逆转多药耐药性。
Carbohydr Polym. 2022 Apr 15;282:119108. doi: 10.1016/j.carbpol.2022.119108. Epub 2022 Jan 11.
10
Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis.发现含有 6,7-甲氧基喹啉结构的 N-(1,3,4-噻二唑-2-基)苯甲酰胺衍生物作为新型 EGFR/HER-2 双重靶标抑制剂,抑制肿瘤生长和血管生成。
Bioorg Chem. 2022 Feb;119:105469. doi: 10.1016/j.bioorg.2021.105469. Epub 2021 Nov 6.